{"id":"https://openalex.org/W2773882736","doi":"https://doi.org/10.1186/s12931-017-0688-5","title":"Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population","display_name":"Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population","publication_year":2017,"publication_date":"2017-12-01","ids":{"openalex":"https://openalex.org/W2773882736","doi":"https://doi.org/10.1186/s12931-017-0688-5","mag":"2773882736","pmid":"https://pubmed.ncbi.nlm.nih.gov/29228950","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5725803"},"language":"en","primary_location":{"id":"doi:10.1186/s12931-017-0688-5","doi":"https://doi.org/10.1186/s12931-017-0688-5","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s12931-017-0688-5","pdf_url":"https://respiratory-research.biomedcentral.com/track/pdf/10.1186/s12931-017-0688-5","source":{"id":"https://openalex.org/S186153782","display_name":"Respiratory Research","issn_l":"1465-9921","issn":["1465-9921","1465-993X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Respiratory Research","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://respiratory-research.biomedcentral.com/track/pdf/10.1186/s12931-017-0688-5","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5052171516","display_name":"Leif Hilding Bjermer","orcid":"https://orcid.org/0000-0002-3441-8099","observed_orcids":["https://orcid.org/0000-0002-3441-8099"]},"institutions":[{"id":"https://openalex.org/I187531555","display_name":"Lund University","ror":"https://ror.org/012a77v79","country_code":"SE","type":"education","lineage":["https://openalex.org/I187531555"]},{"id":"https://openalex.org/I4210137844","display_name":"Sk\u00e5ne University Hospital","ror":"https://ror.org/02z31g829","country_code":"SE","type":"healthcare","lineage":["https://openalex.org/I4210137844"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Leif Bjermer","raw_affiliation_strings":["Department of Respiratory medicine & Allergology, Skane University Hospital, Lund University, Lund, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Respiratory medicine & Allergology, Skane University Hospital, Lund University, Lund, Sweden","institution_ids":["https://openalex.org/I187531555","https://openalex.org/I4210137844"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089056013","display_name":"Job F. M. van Boven","orcid":"https://orcid.org/0000-0003-2368-2262","observed_orcids":["https://orcid.org/0000-0003-2368-2262"]},"institutions":[{"id":"https://openalex.org/I1334415907","display_name":"University Medical Center Groningen","ror":"https://ror.org/03cv38k47","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I1334415907"]},{"id":"https://openalex.org/I169381384","display_name":"University of Groningen","ror":"https://ror.org/012p63287","country_code":"NL","type":"education","lineage":["https://openalex.org/I169381384"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Job F. M. van Boven","raw_affiliation_strings":["Department of General Practice, Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands","Unit of Pharmacoepidemiology & Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of General Practice, Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands","institution_ids":["https://openalex.org/I1334415907","https://openalex.org/I169381384"]},{"raw_affiliation_string":"Unit of Pharmacoepidemiology & Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands","institution_ids":["https://openalex.org/I169381384"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027806905","display_name":"Madlaina Costa\u2010Scharplatz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210116309","display_name":"Novartis (Sweden)","ror":"https://ror.org/01msnnq69","country_code":"SE","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210116309"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Madlaina Costa-Scharplatz","raw_affiliation_strings":["Novartis Sverige AB, T\u00e4by, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Sverige AB, T\u00e4by, Sweden","institution_ids":["https://openalex.org/I4210116309"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090064794","display_name":"Dorothy L. Keininger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Dorothy L. Keininger","raw_affiliation_strings":["Novartis Pharma AG, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104002215","display_name":"Florian S. Gutzwiller","orcid":"https://orcid.org/0000-0001-7754-5744","observed_orcids":["https://orcid.org/0000-0001-7754-5744"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Florian S. Gutzwiller","raw_affiliation_strings":["Novartis Pharma AG, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028740534","display_name":"Karin Lisspers","orcid":"https://orcid.org/0000-0002-3107-4462","observed_orcids":["https://orcid.org/0000-0002-3107-4462"]},"institutions":[{"id":"https://openalex.org/I123387679","display_name":"Uppsala University","ror":"https://ror.org/048a87296","country_code":"SE","type":"education","lineage":["https://openalex.org/I123387679"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Karin Lisspers","raw_affiliation_strings":["Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden","institution_ids":["https://openalex.org/I123387679"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004135550","display_name":"R Mahon","orcid":"https://orcid.org/0009-0007-3500-5951","observed_orcids":["https://orcid.org/0009-0007-3500-5951"]},"institutions":[{"id":"https://openalex.org/I4210154767","display_name":"Novartis (Ireland)","ror":"https://ror.org/04sgnw557","country_code":"IE","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210154767"]}],"countries":["IE"],"is_corresponding":false,"raw_author_name":"Ronan Mahon","raw_affiliation_strings":["Novartis Ireland Limited, Dublin, Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Ireland Limited, Dublin, Ireland","institution_ids":["https://openalex.org/I4210154767"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036638974","display_name":"Petter Olsson","orcid":"https://orcid.org/0000-0002-3913-3914","observed_orcids":["https://orcid.org/0000-0002-3913-3914"]},"institutions":[{"id":"https://openalex.org/I4210116309","display_name":"Novartis (Sweden)","ror":"https://ror.org/01msnnq69","country_code":"SE","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210116309"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Petter Olsson","raw_affiliation_strings":["Novartis Sverige AB, T\u00e4by, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Sverige AB, T\u00e4by, Sweden","institution_ids":["https://openalex.org/I4210116309"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5001192345","display_name":"Nicol\u00e1s Roche","orcid":"https://orcid.org/0000-0002-3162-5033","observed_orcids":["https://orcid.org/0000-0002-3162-5033"]},"institutions":[{"id":"https://openalex.org/I4210092774","display_name":"H\u00f4pital Cochin","ror":"https://ror.org/00ph8tk69","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210092774","https://openalex.org/I4210097159","https://openalex.org/I4210124464"]},{"id":"https://openalex.org/I4210097159","display_name":"Assistance Publique \u2013 H\u00f4pitaux de Paris","ror":"https://ror.org/00pg5jh14","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159"]},{"id":"https://openalex.org/I4387156284","display_name":"Universit\u00e9 Paris Descartes","ror":"https://ror.org/0220k9r37","country_code":"FR","type":"education","lineage":["https://openalex.org/I204730241","https://openalex.org/I4387156284"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"Nicolas Roche","raw_affiliation_strings":["Respiratory and Intensive Care Medicine, Cochin Hospital (AP-HP) and University Paris Descartes, Paris, France. nicolas.roche@aphp.fr","Respiratory and Intensive Care Medicine, Cochin Hospital (AP-HP) and University Paris Descartes, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Respiratory and Intensive Care Medicine, Cochin Hospital (AP-HP) and University Paris Descartes, Paris, France. nicolas.roche@aphp.fr","institution_ids":["https://openalex.org/I4210092774","https://openalex.org/I4210097159","https://openalex.org/I4387156284"]},{"raw_affiliation_string":"Respiratory and Intensive Care Medicine, Cochin Hospital (AP-HP) and University Paris Descartes, Paris, France","institution_ids":["https://openalex.org/I4210092774","https://openalex.org/I4210097159","https://openalex.org/I4387156284"]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":11,"corresponding_author_ids":["https://openalex.org/A5001192345"],"corresponding_institution_ids":["https://openalex.org/I4210092774","https://openalex.org/I4210097159","https://openalex.org/I4387156284"],"apc_list":{"value":3490,"currency":"USD","value_usd":3490},"apc_paid":{"value":3490,"currency":"USD","value_usd":3490},"fwci":0.9039,"has_fulltext":true,"cited_by_count":5,"citation_normalized_percentile":{"value":0.77596814,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"18","issue":"1","first_page":"206","last_page":"206"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10143","display_name":"Chronic Obstructive Pulmonary Disease (COPD) Research","score":0.548799991607666,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10143","display_name":"Chronic Obstructive Pulmonary Disease (COPD) Research","score":0.548799991607666,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.4424000084400177,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11651","display_name":"Inhalation and Respiratory Drug Delivery","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/indacaterol-glycopyrronium","display_name":"indacaterol/glycopyrronium","score":0.9810000061988831},{"id":"https://openalex.org/keywords/salmeterol-fluticasone","display_name":"salmeterol/fluticasone","score":1.0},{"id":"https://openalex.org/keywords/chronic-obstructive-pulmonary-disease","display_name":"chronic obstructive pulmonary disease","score":0.9900000095367432},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9819999933242798},{"id":"https://openalex.org/keywords/patient-level-simulation-model","display_name":"patient-level simulation model","score":0.8500000238418579},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.7870000004768372},{"id":"https://openalex.org/keywords/net-monetary-benefit","display_name":"net monetary benefit","score":0.6909999847412109},{"id":"https://openalex.org/keywords/acute-exacerbation-of-copd","display_name":"COPD exacerbations","score":0.6299999952316284},{"id":"https://openalex.org/keywords/long-acting-muscarinic-antagonist","display_name":"long-acting muscarinic antagonist","score":0.6890000104904175},{"id":"https://openalex.org/keywords/long-acting-beta-agonists","display_name":"long-acting beta2-agonists","score":0.7390000224113464},{"id":"https://openalex.org/keywords/inhaled-corticosteroids","display_name":"inhaled corticosteroids","score":0.7390000224113464}],"concepts":[{"id":"https://openalex.org/C2778884479","wikidata":"https://www.wikidata.org/wiki/Q425654","display_name":"Indacaterol","level":4,"score":0.9484986066818237},{"id":"https://openalex.org/C2776719499","wikidata":"https://www.wikidata.org/wiki/Q424333","display_name":"Salmeterol","level":3,"score":0.8154738545417786},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8055115938186646},{"id":"https://openalex.org/C2776780178","wikidata":"https://www.wikidata.org/wiki/Q199804","display_name":"COPD","level":2,"score":0.713594913482666},{"id":"https://openalex.org/C2777014857","wikidata":"https://www.wikidata.org/wiki/Q1383410","display_name":"Exacerbation","level":2,"score":0.7016469836235046},{"id":"https://openalex.org/C2781212218","wikidata":"https://www.wikidata.org/wiki/Q1002165","display_name":"Fluticasone","level":3,"score":0.6526163816452026},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4582878649234772},{"id":"https://openalex.org/C2779028295","wikidata":"https://www.wikidata.org/wiki/Q8564098","display_name":"Fluticasone propionate","level":3,"score":0.41039323806762695},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3927862048149109},{"id":"https://openalex.org/C194828623","wikidata":"https://www.wikidata.org/wiki/Q2861470","display_name":"Emergency medicine","level":1,"score":0.3525693714618683},{"id":"https://openalex.org/C2776042228","wikidata":"https://www.wikidata.org/wiki/Q35869","display_name":"Asthma","level":2,"score":0.1414961814880371},{"id":"https://openalex.org/C2781018748","wikidata":"https://www.wikidata.org/wiki/Q927234","display_name":"Bronchodilator","level":3,"score":0.11226731538772583},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.09380406141281128}],"mesh":[{"descriptor_ui":"D000068297","descriptor_name":"Fluticasone-Salmeterol Drug Combination","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000068297","descriptor_name":"Fluticasone-Salmeterol Drug Combination","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004338","descriptor_name":"Drug Combinations","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006024","descriptor_name":"Glycopyrrolate","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D006024","descriptor_name":"Glycopyrrolate","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D006024","descriptor_name":"Glycopyrrolate","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007189","descriptor_name":"Indans","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007189","descriptor_name":"Indans","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011159","descriptor_name":"Population Surveillance","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D013548","descriptor_name":"Sweden","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D018803","descriptor_name":"Models, Economic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D029424","descriptor_name":"Pulmonary Disease, Chronic Obstructive","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D029424","descriptor_name":"Pulmonary Disease, Chronic Obstructive","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D029424","descriptor_name":"Pulmonary Disease, Chronic Obstructive","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false}],"locations_count":9,"locations":[{"id":"doi:10.1186/s12931-017-0688-5","doi":"https://doi.org/10.1186/s12931-017-0688-5","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s12931-017-0688-5","pdf_url":"https://respiratory-research.biomedcentral.com/track/pdf/10.1186/s12931-017-0688-5","source":{"id":"https://openalex.org/S186153782","display_name":"Respiratory Research","issn_l":"1465-9921","issn":["1465-9921","1465-993X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Respiratory Research","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:4640614","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5725803","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:5725803","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5725803","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Respir Res","raw_type":"Text"},{"id":"pmid:29228950","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29228950","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Respiratory research","raw_type":"Clinical Trial, Phase III"},{"id":"pmh:oai:pure.rug.nl:openaire/6ed00539-4568-4907-a11a-e1fc2fdc4a7d","doi":null,"is_oa":true,"landing_page_url":"https://research.rug.nl/en/publications/6ed00539-4568-4907-a11a-e1fc2fdc4a7d","pdf_url":null,"source":{"id":"https://openalex.org/S4306400420","display_name":"University of Groningen research database (University of Groningen / Centre for Information Technology)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I169381384","host_organization_name":"University of Groningen","host_organization_lineage":["https://openalex.org/I169381384"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bjermer, L, van Boven, J F M, Costa-Scharplatz, M, Keininger, D L, Gutzwiller, F S, Lisspers, K, Mahon, R, Olsson, P & Roche, N 2017, 'Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD : FLAME-based modelling in a Swedish population', Respiratory Research, vol. 18, 206. https://doi.org/10.1186/s12931-017-0688-5","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:DiVA.org:uu-339803","doi":null,"is_oa":true,"landing_page_url":"http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-339803","pdf_url":null,"source":{"id":"https://openalex.org/S4306401559","display_name":"KTH Publication Database DiVA (KTH Royal Institute of Technology)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I86987016","host_organization_name":"KTH Royal Institute of Technology","host_organization_lineage":["https://openalex.org/I86987016"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:doaj.org/article:a75e575a8368428984f2e17267f9fbb5","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/a75e575a8368428984f2e17267f9fbb5","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Respiratory Research, Vol 18, Iss 1, Pp 1-10 (2017)","raw_type":"article"},{"id":"pmh:oai:lup.lub.lu.se:2f274ec7-ef2d-4584-baf2-f5cf005750b5","doi":null,"is_oa":false,"landing_page_url":"https://lup.lub.lu.se/record/2f274ec7-ef2d-4584-baf2-f5cf005750b5","pdf_url":null,"source":{"id":"https://openalex.org/S4306400536","display_name":"Lund University Publications (Lund University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I187531555","host_organization_name":"Lund University","host_organization_lineage":["https://openalex.org/I187531555"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"ISSN: 1465-9921","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:rug:oai:pure.rug.nl:publications/6ed00539-4568-4907-a11a-e1fc2fdc4a7d","doi":null,"is_oa":true,"landing_page_url":"https://research.rug.nl/en/publications/6ed00539-4568-4907-a11a-e1fc2fdc4a7d","pdf_url":null,"source":{"id":"https://openalex.org/S4306400420","display_name":"University of Groningen research database (University of Groningen / Centre for Information Technology)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I169381384","host_organization_name":"University of Groningen","host_organization_lineage":["https://openalex.org/I169381384"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Respiratory Research, 18:206. BioMed Central Ltd.","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1186/s12931-017-0688-5","doi":"https://doi.org/10.1186/s12931-017-0688-5","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s12931-017-0688-5","pdf_url":"https://respiratory-research.biomedcentral.com/track/pdf/10.1186/s12931-017-0688-5","source":{"id":"https://openalex.org/S186153782","display_name":"Respiratory Research","issn_l":"1465-9921","issn":["1465-9921","1465-993X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Respiratory Research","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320332736","display_name":"Novartis Pharma","ror":"https://ror.org/0013shd50"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2773882736.pdf","grobid_xml":"https://content.openalex.org/works/W2773882736.grobid-xml"},"referenced_works_count":25,"referenced_works":["https://openalex.org/W1496026319","https://openalex.org/W1511765235","https://openalex.org/W1576803907","https://openalex.org/W1595046345","https://openalex.org/W1637753636","https://openalex.org/W1861036421","https://openalex.org/W1968984549","https://openalex.org/W2027648729","https://openalex.org/W2037067833","https://openalex.org/W2110550943","https://openalex.org/W2111374619","https://openalex.org/W2116505643","https://openalex.org/W2127951128","https://openalex.org/W2133986277","https://openalex.org/W2141976863","https://openalex.org/W2148718391","https://openalex.org/W2171314907","https://openalex.org/W2287635305","https://openalex.org/W2330533577","https://openalex.org/W2365138737","https://openalex.org/W2514209421","https://openalex.org/W2517117853","https://openalex.org/W2522108195","https://openalex.org/W2545818057","https://openalex.org/W2782892299"],"related_works":["https://openalex.org/W2777010897","https://openalex.org/W2898519483","https://openalex.org/W2794309092","https://openalex.org/W2564968965","https://openalex.org/W2955065959","https://openalex.org/W3017073610","https://openalex.org/W2517117853","https://openalex.org/W2037067833","https://openalex.org/W2795739321","https://openalex.org/W3131990541"],"abstract_inverted_index":{"BACKGROUND:":[0],"This":[1],"study":[2],"assessed":[3],"the":[4,30,48,56,91,134,181,226],"cost-effectiveness":[5],"of":[6,139,152,174],"indacaterol/glycopyrronium":[7],"(IND/GLY)":[8],"versus":[9],"salmeterol/fluticasone":[10],"(SFC)":[11],"in":[12,29,102,142,180,207,225],"chronic":[13],"obstructive":[14],"pulmonary":[15],"disease":[16],"(COPD)":[17],"patients":[18,209],"with":[19,123,130,149,155,205,210],"moderate":[20,216],"to":[21,166,217],"very":[22,218],"severe":[23,184,219],"airflow":[24,220],"limitation":[25],"and":[26,37,51,67,70,88,95,110,126,146,189,195,222],"\u22651":[27,223],"exacerbation":[28,224],"preceding":[31,227],"year.":[32,228],"METHODS:":[33],"A":[34],"previously":[35],"published":[36],"validated":[38],"patient-level":[39],"simulation":[40],"model":[41,103],"was":[42,106,121,164,178],"adapted":[43],"using":[44],"clinical":[45],"data":[46,54],"from":[47,55,90],"FLAME":[49],"trial":[50],"real-world":[52],"cost":[53,150],"ARCTIC":[57],"study.":[58],"Costs":[59],"(total":[60],"monetary":[61,161],"costs":[62,125],"comprising":[63],"drug,":[64],"maintenance,":[65],"exacerbation,":[66],"pneumonia":[68],"costs)":[69],"health":[71],"outcomes":[72,128],"(life-years":[73],"(LYs),":[74],"quality-adjusted":[75],"life-years":[76],"(QALYs))":[77],"were":[78,96,116],"projected":[79],"over":[80,132,157],"various":[81],"time":[82,136],"horizons":[83],"(1,":[84],"5,":[85],"10":[86],"years,":[87],"lifetime)":[89],"Swedish":[92],"payer's":[93],"perspective":[94],"discounted":[97],"at":[98],"3%":[99],"annually.":[100],"Uncertainty":[101],"input":[104],"values":[105],"studied":[107],"through":[108],"one-way":[109],"probabilistic":[111],"sensitivity":[112],"analyses.":[113],"Subgroup":[114],"analyses":[115],"also":[117],"performed.":[118],"RESULTS:":[119],"IND/GLY":[120,140,199],"associated":[122],"lower":[124],"better":[127],"compared":[129,154,204],"SFC":[131,156,206],"all":[133],"analysed":[135],"horizons.":[137],"Use":[138],"resulted":[141],"additional":[143],"0.192":[144],"LYs":[145],"0.134":[147],"QALYs":[148],"savings":[151],"\u20ac1211":[153],"lifetime.":[158],"The":[159,176],"net":[160],"benefit":[162],"(NMB)":[163],"estimated":[165],"be":[167],"\u20ac8560":[168],"based":[169],"on":[170],"a":[171,201],"willingness-to-pay":[172],"threshold":[173],"\u20ac55,000/QALY.":[175],"NMB":[177],"higher":[179],"following":[182],"subgroups:":[183],"(GOLD":[185,192],"3),":[186],"high":[187],"risk":[188],"more":[190],"symptoms":[191],"D),":[193],"females,":[194],"current":[196],"smokers.":[197],"CONCLUSION:":[198],"is":[200],"cost-effective":[202],"treatment":[203],"COPD":[208],"mMRC":[211],"dyspnea":[212],"grade":[213],"\u2265":[214],"2,":[215],"limitation,":[221]},"counts_by_year":[{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2017-12-22T00:00:00"}